DGAP-Adhoc
Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 - Seite 3
04-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: | English |
Company: | Heidelberg Pharma AG |
Gregor-Mendel-Str. 22 | |
68526 Ladenburg | |
Germany | |
Phone: | +49 (0)89 41 31 38 - 0 |
Fax: | +49 (0)89 41 31 38 - 99 |
E-mail: | investors@hdpharma.com |
Internet: | www.heidelberg-pharma.com |
ISIN: | DE000A11QVV0 |
WKN: | A11QVV |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1165788 |
End of Announcement | DGAP News Service |
|
1165788 04-Feb-2021 CET/CEST
Lesen Sie auch
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte